Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells-Reference-Cited by-同舟云学术

Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells

Published:2020-03-16 Issue:1 Volume:35 Page:156-168
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Best Scott,Lam Vi,Liu Tingting,Bruss Nur,Kittai Adam,Danilova Olga V.,Murray Susan,Berger Allison,Pennock Nathan D.,Lind Evan F.^ORCID,Danilov Alexey V.^ORCID

Funder

Leukemia and Lymphoma Society

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0794-0.pdf

Reference51 articles.

1. Kittai AS, Lunning M, Danilov AV. Relevance of prognostic factors in the era of targeted therapies in CLL. Curr Hematol Malig Rep. 2019;14:302–9.

2. Shindiapina P, Brown JR, Danilov AV. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol. 2014;167:149–61.

3. Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Investig. 2017;127:3052–64.

4. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–49.

5. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Role of Unconventional Post-Translational Modifications in Cancer Diagnostics and Therapy;Current Protein & Peptide Science;2024-12

2. The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway;Biomolecules;2024-06-21

3. Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer;npj Breast Cancer;2024-05-27

4. Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer;Nature Communications;2024-04-27

5. Protein neddylation and its role in health and diseases;Signal Transduction and Targeted Therapy;2024-04-05